Illuminating ctDNA-MRD: Gene Solutions’ K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology

Da Nang, Vietnam – May 9-11, 2025 – Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. —  This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP).

Under the theme “Empowering the Potential of ctDNA-MRD,” 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice.

“While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,” said Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions. “Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.”

“K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact’’ said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. “This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region’’

 

A First-of-Its-Kind Gathering in Asia-Pacific

Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics.

The summit featured three key sessions shared by 16 esteemed experts

K-CONNECT ACADEMIC Session:

  • The Importance of ctDNA-MRD and CGP in Precision Oncology
  • Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring
  • Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors.

K-CONNECT CASE SHARING Session

  • ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers.

K-CONNECT NEXT LANDMARK Session

  • Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors.
  • Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation.

Beyond an Event — Establishing a Platform for Ongoing Impact

K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include:

  • K-CONNECT Webinar Series – Ongoing expert-led case discussions
  • Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions
  • Experience ctDNA-MRD Program – Hands-on implementation support for clinicians
  • Knowledge Hub – A digital platform for APAC oncology insights

Shaping the Future of Cancer Care

K-CONNECT APAC 2025 solidified Gene Solutions’ leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific.

About Gene Solutions

Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring.

With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.

Explore more information at: https://genesolutions.com/

MEDIA CONTACT: [email protected]

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More